


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-27 (canceled)

28 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (I):



(I)

wherein: **X** is -CHR<sub>5</sub>- , -CHR<sub>5</sub>-alkyl-, or -CHR<sub>5</sub>-alkenyl-;

**R**<sub>1</sub> is selected from the group consisting of:

- R<sub>4</sub>-CR<sub>3</sub>-Z-R<sub>6</sub>-alkyl,
- R<sub>4</sub>-CR<sub>3</sub>-Z-R<sub>6</sub>-alkenyl,
- R<sub>4</sub>-CR<sub>3</sub>-Z-R<sub>6</sub>-aryl,
- R<sub>4</sub>-CR<sub>3</sub>-Z-R<sub>6</sub>-heteroaryl,
- R<sub>4</sub>-CR<sub>3</sub>-Z-R<sub>6</sub>-heterocyclyl,
- R<sub>4</sub>-CR<sub>3</sub>-Z-H,
- R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-alkyl,
- R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-alkenyl,
- R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-aryl,
- R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-heteroaryl,
- R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-heterocyclyl, and

-R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>8</sub>;

each Z is independently -NR<sub>5</sub>-, -O-, or -S-;

R<sub>2</sub> is selected from the group consisting of:

-hydrogen,

-alkyl,

-alkenyl,

-aryl,

-heteroaryl,

-heterocyclyl,

-alkyl-Y-alkyl,

-alkyl-Y- alkenyl,

-alkyl-Y-aryl, and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,

-halogen,

-N(R<sub>5</sub>)<sub>2</sub>,

-CO-N(R<sub>5</sub>)<sub>2</sub>,

-CO-C<sub>1-10</sub> alkyl,

-CO-O-C<sub>1-10</sub> alkyl,

-N<sub>3</sub>,

-aryl,

-heteroaryl,

-heterocyclyl,

-CO-aryl, and

-CO-heteroaryl;

each R<sub>3</sub> is =O or =S;

each R<sub>4</sub> is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups;

each R<sub>5</sub> is independently H or C<sub>1-10</sub> alkyl;

**R<sub>6</sub>** is a bond, alkyl, or alkenyl, which may be interrupted by one or more –O– groups;

**R<sub>7</sub>** is H, C<sub>1-10</sub> alkyl, or arylalkyl; or when R<sub>4</sub> is alkyl and R<sub>7</sub> is C<sub>1-10</sub> alkyl, R<sub>4</sub> and R<sub>7</sub> can join together to form a piperidine ring;

**R<sub>8</sub>** is H or C<sub>1-10</sub> alkyl;


each **Y** is independently –O– or –S(O)<sub>0-2</sub>–;

**n** is 0; and

each **R** present is independently selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

29 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (II):



wherein: **X** is –CHR<sub>5</sub>–, -CHR<sub>5</sub>-alkyl-, or -CHR<sub>5</sub>-alkenyl-;

**R<sub>1</sub>** is selected from the group consisting of:

- R<sub>4</sub>–CR<sub>3</sub>–Z–R<sub>6</sub>—alkyl,
- R<sub>4</sub>–CR<sub>3</sub>–Z–R<sub>6</sub>—alkenyl,
- R<sub>4</sub>–CR<sub>3</sub>–Z–R<sub>6</sub>—aryl,
- R<sub>4</sub>–CR<sub>3</sub>–Z–R<sub>6</sub>—heteroaryl,
- R<sub>4</sub>–CR<sub>3</sub>–Z–R<sub>6</sub>—heterocyclyl,
- R<sub>4</sub>–CR<sub>3</sub>–Z–H,

-R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-alkyl,  
-R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-alkenyl,  
-R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-aryl,  
-R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-heteroaryl,  
-R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>6</sub>-heterocyclyl, and  
-R<sub>4</sub>-NR<sub>7</sub>-CR<sub>3</sub>-R<sub>8</sub>;

each Z is independently -NR<sub>5</sub>-, -O-, or -S-;

**R**<sub>2</sub> is selected from the group consisting of:

-hydrogen,  
-alkyl,  
-alkenyl,  
-aryl,  
-heteroaryl,  
-heterocyclyl,  
-alkyl-Y-alkyl,  
-alkyl-Y- alkenyl,  
-alkyl-Y-aryl, and  
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH,  
-halogen,  
-N(R<sub>5</sub>)<sub>2</sub>,  
-CO-N(R<sub>5</sub>)<sub>2</sub>,  
-CO-C<sub>1-10</sub> alkyl,  
-CO-O-C<sub>1-10</sub> alkyl,  
-N<sub>3</sub>,  
-aryl,  
-heteroaryl,  
-heterocyclyl,  
-CO-aryl, and  
-CO-heteroaryl;

each **R**<sub>3</sub> is =O or =S;

each **R**<sub>4</sub> is independently alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each **R**<sub>5</sub> is independently H or C<sub>1-10</sub> alkyl;

**R**<sub>6</sub> is a bond, alkyl, or alkenyl, which may be interrupted by one or more –O– groups;

**R**<sub>7</sub> is H, C<sub>1-10</sub> alkyl, or arylalkyl; or when **R**<sub>4</sub> is alkyl and **R**<sub>7</sub> is C<sub>1-10</sub> alkyl, **R**<sub>4</sub> and **R**<sub>7</sub> can join together to form a piperidine ring;

**R**<sub>8</sub> is H or C<sub>1-10</sub> alkyl;

each **Y** is independently –O– or –S(O)<sub>0-2</sub>–;

**n** is 0; and

each **R** present is independently selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, hydroxy, halogen, and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.